Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours.
Neoplastic meningitis consists of diffuse involvement of the leptomeninges by infiltrating cancer cells, and can be caused by systemic or primary CNS tumours, such as solid cancers or lymphoproliferative malignant disease. Neoplastic meningitis is characterised by multifocal neurological signs and symptoms. Thus, careful neurological examination is needed for diagnosis of secondary diffuse involvement. Survival of patients with neoplastic meningitis is short (3-4 months), although some patients have long-lasting remission. Because most patients with neoplastic meningitis have diffuse systemic disease, treatment is typically palliative. However, more aggressive treatments are available to low-risk patients, which could increase survival. Therefore, identification of low-risk patients is important. Intrathecal chemotherapy is currently the main treatment for patients with neoplastic meningitis, but optimum anticancer chemotherapy is being studied.
Beauchesne
Patrick
P
Neuro-Oncology, Nancy Hospital, France. p.beauchesne@chu-nancy.fr
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D007278:Injections, Spinal; D055756:Meningeal Carcinomatosis / Q000188:drug therapy* / Q000556:secondary*; D008581:Meningitis / Q000209:etiology; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy / Q000473:pathology
D000970:Antineoplastic Agents